Wysoczynski Marcin, Hong Kyung U, Moore Joseph B
University of Louisville, Institute of Molecular Cardiology, Department of Medicine , Louisville, KY , USA.
Expert Opin Biol Ther. 2014 Sep;14(9):1229-32. doi: 10.1517/14712598.2014.925873. Epub 2014 Jun 4.
Decrements in ventricular function due to the permanent loss of contractile tissue remain problematic in patients with ischemic cardiomyopathy. For this reason, cell replacement therapy has received much popularity in recent years. Bone marrow is an abundant and accessible source of stem cells with regenerative potential. However, ischemic heart disease clinical trials based on bone marrow-derived stem cell (BMC) infusion have yielded discrepant results and marginal therapeutic benefits, making this modality's future uncertain. Further investigation of molecular and cellular characteristics critical for therapeutic efficacy and defining the mechanism(s) of BMC-mediated cardiac repair will be paramount for harnessing their full therapeutic potential.
由于收缩组织的永久性丧失导致的心室功能减退在缺血性心肌病患者中仍然是个问题。因此，细胞替代疗法近年来颇受关注。骨髓是具有再生潜力的丰富且易于获取的干细胞来源。然而，基于骨髓来源干细胞（BMC）输注的缺血性心脏病临床试验结果不一，治疗效果有限，使得这种治疗方式的未来充满不确定性。进一步研究对治疗效果至关重要的分子和细胞特征，并明确BMC介导的心脏修复机制，对于充分发挥其治疗潜力至关重要。
